Our computational platform converts recombinant proteins into material-binding variants that can be used to coat implants, devices, and injectable carriers. This novel and unprecedented method enables us to deliver therapeutics to any location in the body with precision.
Proteins in nature did not evolve specifically to treat diseases. Most proteins administered directly as therapeutics often leads to less efficacious and undesired results in patients. Theradaptive seeks to combat this by selecting native proteins, and engineering them to remain local, ensuring precise, targeted delivery, while reducing off-target side effects.
With a combination of computational and in vitro methods we are able to identify variants that have valuable material binding properties.
The output of this process is a novel protein variant that preserves native biological function and that can bind to the selected material with extremely high affinity. This enables new therapeutics that are safer and more effective.
Our modified proteins can be applied easily in a simple one-step process that does not require any chemical modification.
Our material-binding proteins can be used to coat implants, devices, and injectable carriers. Carriers coated with our modified proteins enable long-term local delivery with vastly reduced off target effects.
Every protein we generate with our method is novel composition of matter, thus creating unique and independent IP.
